Aytu BioPharma确保EXXUA专利延期至2030年，扩大FDA CY独占期

Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, today announced that the method of use patent (U.S. Patent No. 7,538,116) for EXXUATM (gepirone) extended-release tablets ("EXXUA") has been extended through September 2, 2030 under 35 U.S.C. 156. The patent extension further expands upon the new chemical entity ("NCE") exclusivity period granted by the United States Food and Drug Administration ("FDA"). Gepirone is an NCE, and EXXUA is the first-in-class selective serotonin 5HT1a receptor agonist approved by the FDA for the treatment of major depressive disorder ("MDD") in adults.